Orencia (Abatacept)

Abatacept is a fusion protein that blocks the CD28‑mediated costimulatory signal required for full T‑cell activation. By preventing this second signal, it reduces the release of inflammatory cytokines that drive autoimmune joint damage.

The dosing regimen for Orencia is individualized by the prescribing clinician based on the patient’s weight, disease severity and prior therapy. The prescriber determines the infusion volume, frequency and any loading doses required.

Safety data for abatacept in pregnancy and lactation are limited. Clinicians should consider potential benefits against unknown risks and discuss options with the patient. Breastfeeding decisions should be made after evaluating drug exposure through milk.

To request Orencia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Orencia targets T‑cell costimulation, whereas other biologics such as TNF‑α inhibitors block tumor necrosis factor pathways. The choice depends on patient response, safety profile, comorbidities and prior treatment history. Some patients who do not respond to TNF inhibitors may benefit from abatacept’s distinct mechanism.

Orencia should be stored at 2 °C to 8 °C (refrigerated) in its original packaging, protected from light. Do not freeze the product or shake the vial, as this may affect stability.

Orencia is given as an intravenous infusion, typically over a period of 30 minutes. The initial dose may be given as a weight‑based loading infusion, followed by maintenance infusions at regular intervals as directed by the prescriber.

Serious risks include severe infections such as pneumonia or sepsis, opportunistic infections like tuberculosis, malignancies including lymphoma, and rare neurological conditions such as progressive multifocal leukoencephalopathy. Patients should be monitored closely for signs of infection or unusual symptoms.

Orencia is contraindicated in patients with known hypersensitivity to abatacept or any component of the formulation, and in those receiving live vaccines. Caution is advised for individuals with active infections, uncontrolled heart failure, or a history of malignancy.